Cellectar Biosciences, Inc. Increase Decrease In Operating Lease Liability
Cellectar Biosciences, Inc. (CLRB) reported Increase Decrease In Operating Lease Liability of $2.75 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$22.34K.
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$21.58K.
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$20.84K.
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$19.65K.
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for fiscal 2025 was -$84.42K.
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for fiscal 2024 was -$58.98K.
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for fiscal 2023 was -$50.85K.
- Cellectar Biosciences, Inc. increase decrease in operating lease liability for fiscal 2022 was -$144.03K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.75K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | -$22.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$43.92K derived: sum of 2 quarters · filed 2026-03-04 | -$64.76K derived: sum of 3 quarters · filed 2026-08-13 | -$84.42K 10-K · filed 2026-03-04 |
| 2025-09-30 | -$21.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$42.42K derived: sum of 2 quarters · filed 2026-08-13 | -$62.07K 10-Q · filed 2025-11-13 | -$80.82K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$20.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$40.49K 10-Q · filed 2026-08-13 | -$59.24K derived: sum of 3 quarters · filed 2026-08-13 | -$77.35K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$19.65K 10-Q · filed 2026-05-14 | -$38.40K derived: sum of 2 quarters · filed 2026-05-14 | -$56.51K derived: sum of 3 quarters · filed 2026-05-14 | -$73.99K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$18.75K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$36.85K derived: sum of 2 quarters · filed 2026-03-04 | -$54.34K derived: sum of 3 quarters · filed 2026-03-04 | -$58.98K 10-K · filed 2026-03-04 |
| 2024-09-30 | -$18.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$35.59K derived: sum of 2 quarters · filed 2025-11-13 | -$40.23K 10-Q · filed 2025-11-13 | -$56.26K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$17.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$22.13K 10-Q · filed 2025-08-14 | -$38.16K derived: sum of 3 quarters · filed 2025-08-14 | -$53.64K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$4.64K 10-Q · filed 2025-05-13 | -$20.67K derived: sum of 2 quarters · filed 2025-05-13 | -$36.15K derived: sum of 3 quarters · filed 2025-05-13 | -$51.11K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$16.03K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$31.51K derived: sum of 2 quarters · filed 2025-03-13 | -$46.47K derived: sum of 3 quarters · filed 2025-03-13 | -$50.85K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$15.48K derived: 10-Q 9 month − 10-K/A 6 month · filed 2024-11-18 | -$30.44K derived: sum of 2 quarters · filed 2024-11-18 | -$34.81K 10-Q · filed 2024-11-18 | -$79.08K derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | -$14.95K derived: 10-K/A 6 month − 10-K/A 3 month · filed 2024-10-29 | -$19.33K 10-K/A · filed 2024-10-29 | -$63.59K derived: sum of 3 quarters · filed 2024-10-29 | -$97.68K derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-03-31 | -$4.38K 10-K/A · filed 2024-10-29 | -$48.64K derived: sum of 2 quarters · filed 2024-10-29 | -$82.73K derived: sum of 3 quarters · filed 2024-10-29 | -$115.98K derived: sum of 4 quarters · filed 2024-10-29 |
| 2022-12-31 | -$44.26K derived: 10-K/A 12 month − 10-K/A 9 month · filed 2024-10-29 | -$78.35K derived: sum of 2 quarters · filed 2024-10-29 | -$111.60K derived: sum of 3 quarters · filed 2024-10-29 | -$144.03K 10-K/A · filed 2024-10-29 |
| 2022-09-30 | -$34.09K derived: 10-K/A 9 month − 10-K/A 6 month · filed 2024-10-29 | -$67.34K derived: sum of 2 quarters · filed 2024-10-29 | -$99.77K 10-K/A · filed 2024-10-29 | -$131.41K derived: sum of 4 quarters · filed 2024-10-29 |
| 2022-06-30 | -$33.25K derived: 10-K/A 6 month − 10-K/A 3 month · filed 2024-10-29 | -$65.68K 10-K/A · filed 2024-10-29 | -$97.32K derived: sum of 3 quarters · filed 2024-10-29 | -$127.48K derived: sum of 4 quarters · filed 2024-10-29 |
| 2022-03-31 | -$32.43K 10-K/A · filed 2024-10-29 | -$64.07K derived: sum of 2 quarters · filed 2024-10-29 | -$94.23K derived: sum of 3 quarters · filed 2024-10-29 | -$123.64K derived: sum of 4 quarters · filed 2024-10-29 |
| 2021-12-31 | -$31.64K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$61.79K derived: sum of 2 quarters · filed 2023-03-09 | -$91.21K derived: sum of 3 quarters · filed 2023-03-09 | -$119.90K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$30.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$59.58K derived: sum of 2 quarters · filed 2022-11-03 | -$88.27K 10-Q · filed 2022-11-03 | -$116.26K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$29.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$58.11K 10-Q · filed 2022-08-05 | -$86.10K derived: sum of 3 quarters · filed 2022-08-05 | |
| 2021-03-31 | -$28.69K 10-Q · filed 2022-05-10 | -$56.68K derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | -$27.99K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$105.89K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$77.90K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |